According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “
Shares of VCNX stock traded down $0.39 during trading hours on Wednesday, reaching $6.62. 300 shares of the stock traded hands, compared to its average volume of 11,181. Vaccinex has a 1-year low of $3.32 and a 1-year high of $12.00. The firm has a market capitalization of $80.47 million and a P/E ratio of -1.28.
Institutional investors and hedge funds have recently bought and sold shares of the business. Telemetry Investments L.L.C. increased its position in Vaccinex by 26.3% in the 4th quarter. Telemetry Investments L.L.C. now owns 14,720 shares of the company’s stock valued at $54,000 after acquiring an additional 3,066 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Vaccinex in the 3rd quarter valued at about $124,000. Vanguard Group Inc. bought a new position in shares of Vaccinex in the 3rd quarter valued at about $341,000. Finally, Vanguard Group Inc bought a new position in shares of Vaccinex in the 3rd quarter valued at about $341,000. Hedge funds and other institutional investors own 2.10% of the company’s stock.
Vaccinex Company Profile
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
Further Reading: How does inflation affect different investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.